Less Ads, More Data, More Tools Register for FREE

UPDATE 1-Merck KGaA seeks partner for immuno-oncology drug by year-end

Thu, 18th Sep 2014 10:12

* Competitive process to find partner for anti-PD-L1 drug

* Experimental drug in hot new area for cancer research

* Merck plans increased investment in biosimilar drugs

* Pharma head Oschmann appointed deputy CEO (Adds details on drug, wraps in management changes)

FRANKFURT, Sept 18 (Reuters) - German drugs and chemicals maker Merck KGaA is in advanced talks with potential partners interested in its experimental cancer immunotherapy drug and expects to clinch a partnership deal before the end of the year.

Its medicine is a so-called anti-PD-L1 agent, one of a number of new drugs from rival companies within the hot research area of immuno-oncology that are designed to make tumour cells more vulnerable to attack by the body's immune system.

U.S.-based Merck & Co, Bristol-Myers Squibb, Roche and AstraZeneca are viewed as the main players in this new field, which analysts believe could develop into a market worth tens of billions of dollars in annual sales.

As a mid-sized competitor, Merck KGaA has decided to seek a partner for its product, which has already been given to more than 500 patients in early-stage Phase I tests and is seen as a potential treatment in lung, ovarian and Merkel cell skin cancer.

"We have initiated a competitive process to select the best partner for the global co-development and co-commercialisation of our anti-PD-L1 compound," Stefan Oschmann, the head of its pharma business, said in a statement on Thursday.

"We are currently in advanced discussions with major oncology players and aim to reach an agreement by year-end."

Merck added that it planned to invest an additional 130 to 150 million euros ($168 to $192 million) next year in its unit developing cheaper copies of biotech drugs, known as biosimilars, on top of 100 million euros this year, depending on the outcome of ongoing clinical studies.

It said it would expand existing partnerships with India's Dr Reddy's and Brazil's Bionovis with another, as yet undisclosed in-licensing agreement for a late-stage biosimilar, initially for smaller emerging markets.

The Darmstadt-based company also announced it had appointed the head of its pharma business, Stefan Oschmann, as deputy chief executive.

Oschmann, 57, will share strategic management functions and representation of the company with CEO Karl-Ludwig Kley as of Jan. 1, 2015, putting him in the frame to possibly succeed Kley, whose contract runs until September 2016.

Belen Garijo, 54, will take over leadership of the entire pharma business. Garijo is already CEO of Merck's biopharmaceutical division, Merck Serono, to which she will add consumer health, allergy treatments and biosimilars. (1 US dollar = 0.7759 euro) (Reporting by Georgina Prodhan and Ben Hirschler; Editing by David Holmes)

Related Shares

More News

Inovio Pharmaceuticals's Covid-19 vaccine triggers immune response

(Sharecast News) - Inovio Pharmaceuticals's experimental vaccine against the novel coronavirus was found to be safe in an early stage clinical trial and successfully induced an immune response in the majority of participants in the test.

30 Jun 20 18:34

AstraZeneca Drug Selumetinib Gets Orphan Drug Designation In Japan

AstraZeneca Drug Selumetinib Gets Orphan Drug Designation In Japan

30 Jun 20 09:24

AstraZeneca neurofibromatosis treatment gets orphan drug designation in Japan

(Sharecast News) - AstraZeneca said on Tuesday that selumetinib, its treatment for genetic disease neurofibromatosis type 1, has been granted orphan drug designation in Japan.

30 Jun 20 08:07

Single course of Covid-19 treatment to cost $2,340 per patient - Gilead

(Sharecast News) - Gilead Sciences has announced it will charge developed countries $390 a vial for remdesivir, its antiviral drug currently being investigated for use in Covid-19 patients.

29 Jun 20 12:00

Login to your account

Don't have an account? Click here to register.